Expanded Low Allele Frequency RAS and BRAF V600E Testing in Metastatic Colorectal Cancer as Predictive Biomarkers for Cetuximab in the Randomized CO.17 Trial.

Jonathan M LoreeAnthony DowersDongsheng TuDerek J JonkerDaniel L EdelsteinHannah QuinnFrank HoltrupTimothy PriceJohn R ZalcbergMalcolm J MooreChristos S KarapetisChris J O'CallaghanPaul WaringHagen F KenneckeStanley R HamiltonScott Kopetz

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

We establish single-agent cetuximab efficacy in optimally selected patients and show that subclonal RAS/BRAF alterations are uncommon and remain of indeterminate significance.

Keyphrases

metastatic colorectal cancer
wild type
end stage renal disease
phase iii
ejection fraction
phase ii
chronic kidney disease
newly diagnosed
double blind
clinical trial
open label
study protocol
peritoneal dialysis
randomized controlled trial
squamous cell carcinoma
radiation therapy
locally advanced